U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07657767) titled 'Extracorporeal cfDNA Removal in Septic Shock Patients With Elevated DNA Levels' on June 13.
Brief Summary: modern medicine, associated with profound morbidity and high mortality rates. As a clinical syndrome characterized by a dysregulated systemic response to infection, its progression toward life-threatening organ dysfunction is driven by an array of signaling molecules. Extracorporeal therapy has emerged as a key adjunctive strategy for the targeted elimination of these inflammatory mediators. While current modalities - including non-selective cytokine adsorption, selective LPS-adsorption, and therapeutic plasma exchange (TPE) - ...